
The European Medicines Agency (EMA) is analyzing data from Pfizer, which is seeking approval for its Covid-19 vaccine Comirnaty for use as booster dose.
The idea is to use Comirnaty for the re-vaccination of patients aged 16 or older six months after they have received their second dose. The purpose is to restore the protection against Covid-19 before it wanes, the EMA writes on its website.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app